Bone Biologics Co. (OTC:BBLG – Get Free Report) shares dropped 1.9% during trading on Tuesday . The company traded as low as $1.01 and last traded at $1.02. Approximately 44,014 shares traded hands during mid-day trading, a decline of 80% from the average daily volume of 216,571 shares. The stock had previously closed at $1.04.
Bone Biologics Stock Performance
The company has a market cap of $2.54 million, a price-to-earnings ratio of -0.02 and a beta of 0.55. The company has a fifty day moving average of $1.04 and a two-hundred day moving average of $1.37.
Bone Biologics Company Profile
Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBM, an osteopromotive recombinant protein that provides target specific control over bone regeneration. It also develops NELL-1/DBM Fusion Device for use in spinal fusion procedures in skeletally mature patients with spinal degenerative disc disease at one level from L2-S1.
Recommended Stories
- Five stocks we like better than Bone Biologics
- Manufacturing Stocks Investing
- Hims & Hers Earnings Could Be a Game Changer—What to Do Now
- Conference Calls and Individual Investors
- DeepSeek IPO Remains Far Off—Investors Eye 4 Chinese AI Stocks
- Dividend Payout Ratio Calculator
- Mortgage Market Bottom? Why Rocket Companies Could Be a Buy
Receive News & Ratings for Bone Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bone Biologics and related companies with MarketBeat.com's FREE daily email newsletter.
